A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Complete response rate

Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Time frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6）(each cycle is 28 days)

Progression-free survival

Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Time frame: Baseline up to data cut-off (up to approximately 2 years)

Overall survival

Overall survival was defined as the time from the date of enrollment to the date of death from any cause.

Time frame: Baseline up to data cut-off (up to approximately 2 years)

Duration of response

Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria

Time frame: Baseline up to data cut-off (up to approximately 2 years)

Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.